(oteseconazole) is the first FDA-approved treatment for women experiencing chronic yeast infections, specifically recurrent vulvovaginal candidiasis (RVVC), who are either postmenopausal or permanently unable to conceive
(oteseconazole) is the first FDA-approved treatment for women experiencing chronic yeast infections, specifically recurrent vulvovaginal candidiasis (RVVC), who are either postmenopausal or permanently unable to conceive